Endothelin Receptor Antagonism: A New Era in the Treatment of Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
doi 10.21693/1933-088x-1.1.13
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Pulmonary Hypertension Association

Related search

The New Endothelin Receptor Antagonist Macitentan: Prospects for Therapy of Pulmonary Arterial Hypertension

Terapevticheskii Arkhiv
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

New Treatment Options for Pulmonary Arterial Hypertension — The First Selective IP-receptor Agonist Selexipag

Cardiovascular Therapy and Prevention (Russian Federation)
Cardiovascular MedicineCardiology
2019English

Treatment of Pulmonary Arterial Hypertension in Pregnancy

American Journal of Health-System Pharmacy
MedicineHealth PolicyPharmacologyPharmacy
2007English

New Possibilities in the Treatment of Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension in Ukraine

HYPERTENSION
2018English

Surgical Treatment of Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2010English

Endothelin-1 Predicts Hemodynamically Assessed Pulmonary Arterial Hypertension in HIV Infection

PLoS ONE
Multidisciplinary
2016English

Selective endothelinA Receptor Antagonism With Sitaxsentan for Pulmonary Arterial Hypertension Associated With Connective Tissue Disease

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2007English

Selexipag for the Treatment of Pulmonary Arterial Hypertension

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2016English

Selexipag for the Treatment of Pulmonary Arterial Hypertension

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy